高级搜索
赵贯建, 张翔, 程远, 王志刚, 黄琴. 新型NGR靶向载shRNA脂质微球抑制胶质瘤的生长[J]. 肿瘤防治研究, 2019, 46(8): 677-682. DOI: 10.3971/j.issn.1000-8578.2019.18.1990
引用本文: 赵贯建, 张翔, 程远, 王志刚, 黄琴. 新型NGR靶向载shRNA脂质微球抑制胶质瘤的生长[J]. 肿瘤防治研究, 2019, 46(8): 677-682. DOI: 10.3971/j.issn.1000-8578.2019.18.1990
ZHAO Guanjian, ZHANG Xiang, CHENG Yuan, WANG Zhigang, HUANG Qin. New NGR-targeted shRNA-loaded Liposome Suppresses Glioma Growth[J]. Cancer Research on Prevention and Treatment, 2019, 46(8): 677-682. DOI: 10.3971/j.issn.1000-8578.2019.18.1990
Citation: ZHAO Guanjian, ZHANG Xiang, CHENG Yuan, WANG Zhigang, HUANG Qin. New NGR-targeted shRNA-loaded Liposome Suppresses Glioma Growth[J]. Cancer Research on Prevention and Treatment, 2019, 46(8): 677-682. DOI: 10.3971/j.issn.1000-8578.2019.18.1990

新型NGR靶向载shRNA脂质微球抑制胶质瘤的生长

New NGR-targeted shRNA-loaded Liposome Suppresses Glioma Growth

  • 摘要:
    目的 制备一种新型的NGR靶向载shRNA脂质体,研究其对大鼠原位胶质瘤的抑制作用。
    方法 (1)先后制备脂质微球(lipo)、NGR靶向微球(lipo-NGR)和含质粒靶向微球(shBirc5-lipo-NGR),并对各种微球的性质进行表征;(2)免疫组织化学法研究shBirc5-lipo-NGR对大鼠原位胶质瘤模型的靶向性;(3)MRI T2实时监测原位胶质瘤生长情况及观察大鼠生存期。
    结果 (1)成功制备了新型脂质体shBirc5-lipo-NGR,其粒径和电位分别为(186.2±74.07)nm和(10.9±3.76)mV;(2)shBirc5-lipo-NGR组Birc5蛋白较shBirc5-lipo、shControl-lipo-NGR及对照组明显减少;(3)MRI T2显示在成瘤后的第12、17和22天时,对照组肿瘤的平均体积及生长速度是shBirc5-lipo-NGR组的4.7倍左右(P < 0.05)。shBirc5-lipo-NGR、shBirc5-lipo、shControl-lipo-NGR及对照组的中位生存期分别为30、24、22和21天。
    结论 成功制备了新型NGR靶向载shRNA脂质体,将其应用于治疗SD大鼠原位胶质瘤,显示出了明显的肿瘤靶向性,同时具有抑制肿瘤生长、延长大鼠生存期的作用。

     

    Abstract:
    Objective To prepare the new NGR-targeted shRNA-loaded liposome, and investigate its suppressing effect on orthotopic C6 glioma in rats.
    Methods (1) Liposome(lipo), the NGR-targeted liposome (lipo-NGR) and shBirc5-loaded lipo-NGR were prepared successively, and all kinds of products were characterized accordingly; (2) The targeting property of shBirc5-lipo-NGR was researched by immunohistochemical method in orthotopic C6 glioma rats model; (3) The tumor growth in treated rats was monitored longitudinally with MRI T2, and the survival time of each rat was recorded simultaneously.
    Results (1) We successfully prepared shBirc5-lipo-NGR whose size and zeta potential were (186.2±74.07)nm and (10.9±3.76)mV; (2) The Birc5 protein was significantly decreased in shBirc5-lipo-NGR group, compared with shBirc5-lipo group, shControl-lipo-NGR group and control group; (3) The control group exhibited an average tumor volume and growth rate 4.7 times greater than that in the shBirc5-lipo-NGR group on the 12th, 17th and 22th day(P < 0.05). The median survival times of the shBirc5-lipo-NGR, shBirc5-lipo, shControl-lipo-NGR and control groups were 30, 24, 22, 21 days, respectively.
    Conclusion We successfully prepare the new NGR-targeted shRNA-loaded liposome, and demonstrate its targeting property, obvious inhibitory effect on tumor growth and extending the survival time of orthotopic C6 glioma-bearing rats.

     

/

返回文章
返回